OPK - オプコ・ヘルス (Opko Health Inc.) オプコ・ヘルス

 OPKのチャート


 OPKの企業情報

symbol OPK
会社名 Opko Health Inc (オプコ・ヘルス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 OPKO Health Inc. is a healthcare company. Its segments include Pharmaceutical Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile Mexico Ireland Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations. Through Bio-Reference it operates laboratory divisions such as Bio-Reference GenPath (Oncology) GenPath (Women's Health) GeneDx and Laboratorio Bueno Salud. As of December 31 2016 it had one commercial stage pharmaceutical product and several pharmaceutical compounds and technologies in various stages of research and development for a range of indications and conditions including Renal Products Biologics hGH-CTP Factor VII Oxyntomodulin active pharmaceutical ingredients Oligonucleotide Therapeutics NK-1 Program Asthma and chronic obstructive pulmonary disease.   オプコ・ヘルスは、米国のバイオ医薬品および診断法開発会社。ポイントオブケア検査、デベロップメントテスト、分子診断テスト、および独自の医薬品やワクチンなどによる診断、治療、予防法を開発。また、前立腺癌の検査薬を開発するほか、二次副甲状腺機能亢進症を治療するためのビタミンDプロホルモンなど研究開発のための医薬化合物を手掛ける。   Opko Health Inc. is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development, and commercialization expertise and novel and proprietary technologies.
本社所在地 4400 Biscayne Blvd. Miami FL 33137 USA
代表者氏名 Phillip Frost フィリップフロスト
代表者役職名 Chairman of the Board Chief Executive Officer 取締役会長兼最高経営責任者
電話番号 +1 305-575-4138
設立年月日 33512
市場名 NYSE(ニューヨーク証券取引所)
ipoyear ―年
従業員数 5936人
url www.opko.com
nasdaq_url https://www.nasdaq.com/symbol/opk
adr_tso
EBITDA EBITDA(百万ドル) -151.44300
終値(lastsale) 3.68
時価総額(marketcap) 2059957261.6
時価総額 時価総額(百万ドル) 29.578
売上高 売上高(百万ドル) 975.79400
企業価値(EV) 企業価値(EV)(百万ドル) 2138.946
当期純利益 当期純利益(百万ドル) -309.66200
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Opko Health Inc. revenues decreased 7% to $518.6M. Net loss decreased 4% to $49.3M. Revenues reflect Diagnostics segment decrease of 12% to $427.4M Pharmaceutical segment decrease of 29% to $56.4M United States segment decrease of 16% to $437.8M Israel segment decrease of 48% to $6.1M Ireland segment decrease of 11% to $38.1M. Lower net loss reflects Pharmaceutical segment loss decrease of 40% to $20.8M.

 OPKのテクニカル分析


 OPKのニュース

   OPKO Health: A Great Long-Term Investment In Health  2022/04/05 22:11:01 Seeking Alpha
   Opko Health – Consensus Indicates Potential 94.4% Upside  2022/04/01 12:20:59 DirectorsTalk
Opko Health with ticker code (OPK) now have 4 analysts covering the stock with the consensus suggesting a rating of ''Buy''. The range between the high target price and low target price is between 8.5 and 5.5 calculating the average target price we see 6.88. Now with the previous closing price of 3.54 this would indicate that there is a potential upside of 94.4%. There is a 50 day moving average of 3.28 and the 200 day moving average is 3.77. The market capitalisation for the company is $2,344m. Company Website: https://www.opko.com [stock_market_widget type="chart" template="basic" color="green" assets="OPK" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $4,556m based on the market concensus. OPKO Health, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company''s Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women''s health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units; and a novel diagnostic instrument system to provide blood test results in the point-of-care setting, as well as 4Kscore prostate cancer testing services.
   OPKO Health Is Risky But Might Make You Money  2022/03/29 22:39:09 Seeking Alpha
   OPKO Health CEO raises his take at the company further (NASDAQ:OPK)  2022/03/15 16:43:36 Seeking Alpha
COVID-19 test maker, OPKO Health <> is trading higher on Tuesday after Chief Executive and Chairman, Dr
   OPKO Health''s unit, Saol Therapeutics team up to detect patients with rare disease  2022/03/01 11:27:03 Seeking Alpha
Saol Therapeutics is collaborating with OPKO Health''s (OPK) unit GeneDx to help in identifying patients diagnosed with a rare mitochondrial disease, Pyruvate Dehydrogenase…
   OPKO Health: A Great Long-Term Investment In Health  2022/04/05 22:11:01 Seeking Alpha
   Opko Health – Consensus Indicates Potential 94.4% Upside  2022/04/01 12:20:59 DirectorsTalk
Opko Health with ticker code (OPK) now have 4 analysts covering the stock with the consensus suggesting a rating of ''Buy''. The range between the high target price and low target price is between 8.5 and 5.5 calculating the average target price we see 6.88. Now with the previous closing price of 3.54 this would indicate that there is a potential upside of 94.4%. There is a 50 day moving average of 3.28 and the 200 day moving average is 3.77. The market capitalisation for the company is $2,344m. Company Website: https://www.opko.com [stock_market_widget type="chart" template="basic" color="green" assets="OPK" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $4,556m based on the market concensus. OPKO Health, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company''s Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women''s health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units; and a novel diagnostic instrument system to provide blood test results in the point-of-care setting, as well as 4Kscore prostate cancer testing services.
   OPKO Health Is Risky But Might Make You Money  2022/03/29 22:39:09 Seeking Alpha
   OPKO Health CEO raises his take at the company further (NASDAQ:OPK)  2022/03/15 16:43:36 Seeking Alpha
COVID-19 test maker, OPKO Health <> is trading higher on Tuesday after Chief Executive and Chairman, Dr
   OPKO Health''s unit, Saol Therapeutics team up to detect patients with rare disease  2022/03/01 11:27:03 Seeking Alpha
Saol Therapeutics is collaborating with OPKO Health''s (OPK) unit GeneDx to help in identifying patients diagnosed with a rare mitochondrial disease, Pyruvate Dehydrogenase…
   Important Factors to Analyze A Good Investment: OPKO Health, Inc. (NASDAQ:OPK), Great Panther Mining Limited (AMEX:GPL)  2021/06/29 22:55:26 Stock Equity
OPKO Health, Inc. (OPK) with the stream of 3.71% also noticed, India Great Panther Mining Limited (GPL) encountered a rapid change of -3.43% in the last hour of Tuesdays trading The post Important Factors to Analyze A Good Investment: OPKO Health, Inc. (NASDAQ:OPK), Great Panther Mining Limited (AMEX:GPL) appeared first on Stocks Equity .
   Prostate Cancer Diagnostics Market 2021 Overwhelming Extensive Business Opportunities by Maintaining A Strong Outlook Till 2028 | Top Key Players: MDxHealth,3D Signatures,Genomic Health,Abbott,OPKO Health, INC & More  2021/06/28 21:48:00 iCrowdNewswire
The Insight Partners announces the research on Global Prostate Cancer Diagnostics Market as it covers the key boundaries required for your Research Need. This Global Prostate Cancer Diagnostics Market Report []
   Global Clinical Laboratory Tests Market 2021 COVID-19 Impact Analysis, Demand, Growth, Technology Trends, Key Findings And Forecasts By 2028 || Abbott ARUP Laboratories OPKO Health, Inc. Bioscientia Institute for Medical Diagnostics GmbH  2021/06/23 03:23:17 OpenPR
Global Clinical Laboratory Tests Market report is a complete overview of the market that covers various aspects of product definition, market segmentation based on various parameters, and the existing vendor landscape. Company snapshot, geographical presence, product portfolio, and recent developments
   OPKO Health subsidiary partners with Royal Caribbean for COVID-19 testing program  2021/06/22 12:17:20 Seeking Alpha
   OPKO Health Appoints Katherine Stueland as President and CEO of GeneDx  2021/06/22 12:00:00 OPKO Health
MIAMI, June 22, 2021 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced the appointment of Katherine Stueland as President

 関連キーワード  (医薬品 米国株 オプコ・ヘルス OPK Opko Health Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)